Description
What it is — The only GHRH analog — originally developed for HIV-associated visceral adiposity research and sold pharmaceutically as Egrifta. Why it’s studied — Tesamorelin stimulates the pituitary to release growth hormone in natural pulses, elevating IGF-1 selectively. Its FDA-approval pathway makes it one of the best-documented GHRH analogs in research. Key research findings
-
15–18% reduction in visceral adipose tissue at 26 weeks (Falutz et al., Phase 3 trials)
-
Significant IGF-1 elevation without affecting subcutaneous fat
-
No documented impact on insulin sensitivity in published clinical data
